Synthesis of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2,3- benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists

Journal of Medicinal Chemistry

Volumn 41, Issue 14, 1998, Pages 2621-2625

  Wang, Yan ^a   Konkoy, Christopher S ^a   Ilyin, Victor I ^a   Vanover, Kimberly E ^a   Carter, Richard B ^a   Weber, Eckard ^a   Keana, John F W ^a   Woodward, Richard M ^a   Cai, Sui Xiong ^a  

^a Department of Pharmacokinetics and Drug Metabolism   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 7,8 (METHYLENEDIOXY) 3,5 DIHYDRO 4H 2,3 BENZODIAZEPIN 4 ONE; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CONVULSION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; XENOPUS;

ALLOSTERIC REGULATION; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; AZEPINES; BENZODIAZEPINES; CEREBRAL CORTEX; ELECTROSHOCK; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMBRANE POTENTIALS; MICE; OOCYTES; RATS; RECEPTORS, AMPA; RNA, MESSENGER; SEIZURES; XENOPUS LAEVIS;

EID: 0032474755     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980168j     Document Type: Article

References (28)

1. Monaghan, D. T.; Bridges, R. J.; Cotman, C. W. The Excitatory Amino Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the Function of the Central Nervous System. Annu. Rev. Pharmacol. Toxicol. 1989, 29, 365-402.
2. Choi, D. W. Glutamate Neurotoxicity and Diseases of the Nervous System. Neuron 1988, 1, 623-634.
3. (a) Meldrum, B.; Garthwaite, J. Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease. Trends Pharmacol. Sci. 1990, 11, 379-387.
4. (b) Gill, R.; Lodge, D. Pharmacology of AMPA Antagonists and Their Role in Neuroprotection. Neuroprotective Agents and Cerebral Ischemia; Academic Press: San Diego, 1997; pp 197-232.
5. Lipton, S. T.; Rosenberg, P. A. Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders. N. Engl. J. Med. 1994, 330, 613-622.
6. Hollmann, M.; Heinemann, S. Cloned Glutamate Receptors. Annu. Rev. Neurosci. 1994, 17, 31-108.
7. Ozawa, S.; Rossier, J. Molecular Basis for Functional Differences of AMPA-Subtype Glutamate Receptors. News Physiol. Sci. 1996, 11, 77-82.
8. Bigge, C. F.; Boxer, P. A.; Ortwine, D. F. AMPA/Kainate Receptors. Curr. Pharm. Des. 1996, 2, 397-412.
9. Chapman, A. G.; Smith, S. E.; Meldrum, B. S. The Anticonvulsant Effects of the Non-NMDA Antagonists, NBQX and GYKI 52466, in Mice. Epilepsy Res. 1991, 9, 92-96.
10. (a) Xue, D.; Huang, Z-G.; Barnes, K.; Lesiuk, H. J.; Smith, K. E.; Buchan, A. M. Delayed Treatment with AMPA, but not NMDA, Antagonists Reduces Neocortical Infarction. J. Cereb. Blood Flow Metab. 1994, 14, 251-261.
11. (b) Liu, S.; Ruens, G. L.; Yezierski, R. P. NMDA and non-NMDA receptor antagonists protect against excitotoxic injury in the rat spinal cord. Brain Res. 1997, 756, 160-166.
12. Buchan, A. M.; Lesiuk, H.; Barnes, K. A.; Li, H.; Huang, Z.-G.; Smith, K. E.; Xue, D. AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists? Stroke 1993, 24 (Suppl I), I-148-152.
13. (a) Donevan, D. D.; Rogawski, M. A. GYKI 52466, a 2,3-Benzodiazepine, is a Highly Selective, Noncompetitive Antagonist of AMPA/Kainate Receptor Responses. Neuron 1993, 10, 51-59.
14. (b) Zorumski, C. F.; Yamada, K. A.; Price, M. D.; Olney, J. W. Benzodiazepine Recognition Site Associated with Non-NMDA Glutamate Receptor. Neuron 1993, 10, 61-67.
15. (a) Vizi, E. S.; Mike, A.; Tarnawa, I. 2,3-Benzodiazepines (GYKI 52466 and Analogs): Negative Allosteric Modulators of AMPA Receptors. CNS Drug Rev. 1996, 2, 91-126.
16. (b) Lodge, D.; Bond, A.; O'Neill, M. J.; Hicks, C. A.; Jones, M. G. Stereoselective Effects of 2,3-benzodiazepines In Vivo. Electrophysiology and Neuroprotection Studies. Neuropharmacology 1996, 35, 1681-1688.
17. Pelletier, J. C.; Hesson, D. P.; Jones, K. A.; Costa, A.-M. Substituted 1,2-Dihydrophthalazines: Potent, Selective, and Noncompetitive Inhibitors of the AMPA Receptor. J. Med. Chem. 1996, 39, 343-346.
18. Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Grasso, S.; Quartarone, S.; Zappala, M.; Giusti, P.; Libri, V.; Constanti, A.; Chapman, A. G. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: Novel AMPA Receptor Antagonists. J. Med. Chem. 1997, 40, 1258-1269.
19. Bradshaw, D. P.; Jones, D. W.; Tideswell, J. 2-Benzopyran-3-ones Stabilized by Alkoxy substituents. J. Chem. Soc., Perkin Trans. 1 1991, 169-173.
20. 2 Receptor Antagonists: Potential Atypical Antipsychotic Agents. J. Med. Chem. 1994, 37, 2552-2563.
21. Venkov, A. P.; Ivanov, I. I. Synthesis of 3-Oxo-2,3-Dihydroisoquinolines from Ethyl 2-Acylphenylacetates and Formamides. Synth. Commun. 1994, 24, 1145-1150.
22. Woodward, R. M.; Huettner, J. E.; Guastella, J.; Keana, J. F. W.; Weber, E. In Vitro Pharmacology of ACEA 1021 and ACEA 1031: Systemically Active Quinoxalinediones with High Affinity and Selectivity for N-Methyl-D-Aspartate Receptor Glycine Binding Sites. Mol. Pharmacol. 1995, 47, 568-581.
23. Ilyin, V. I.; Whittemore, E. R.; Guastella, J.; Weber, E.; Woodward, R. M. Subtype-Selective Inhibition of NMDA Receptors by Haloperidol. Mol. Pharmacol 1996, 50, 1541-1550.
24. Zar, J. H. Biostatistical Analysis; Prentice-Hall: Englewood Cliffs, NJ, 1974; p 620.
25. Litchfield, J. T.; Wilcoxon, F. A Simplified Method of Evaluating Dose-Effects Experiments. J. Pharmacol. Exp. Ther. 1949, 96, 99-113.
26. A Receptor α4 Subunit Expressed in Xenopus laevis Oocytes. Mol. Pharmacol. 1996, 50, 1364-1375.
27. Horvath, K.; Andrasi, F.; Berzsenyi, P.; Patfalusi, M.; Patthy, M.; Szabo, G.; Sebestyen, L.; Bagdy, E.; Korosi, J.; Botka, P.; Hamori, T.; Lang, T. A New Psychoactive 5H-2,3-Benzodiazepine with a Unique Spectrum of Activity. Arzneim.-Forsch. 1989, 39, 894-899.
28. A receptors. J. Med. Chem. 1997, 40, 73-84.